药品管理新规5月施行，修改条款超90%

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" introduces significant changes aimed at accelerating drug approval processes and enhancing innovation in the pharmaceutical industry, set to take effect on May 15, 2026 [2][15]. Group 1: Regulatory Changes - The revised regulations include four accelerated drug approval pathways and establish market exclusivity periods for pediatric and rare disease drugs [2][22]. - Over 90% of the provisions in the regulations have been modified, reflecting a comprehensive update since the last major revision in 2002 [2][15]. - The shift in focus from managing pharmaceutical companies to managing drug marketing authorization holders emphasizes accountability throughout the drug lifecycle [9][23]. Group 2: Impact on Innovation - The regulations support research and development (R&D) innovation, emphasizing clinical value as a core principle for drug development [4][17]. - The tightening of R&D and registration management is expected to phase out "Me-too" projects, directing resources towards original innovations and first-in-class drugs [4][18]. - The average review time for innovative drugs has decreased by 25% since 2018, with significant numbers of drugs entering accelerated approval programs [5][18]. Group 3: Market Dynamics - The regulations are anticipated to intensify competition, requiring domestic pharmaceutical companies to compete directly with international firms [6][21]. - The introduction of market exclusivity for pediatric and rare disease drugs is expected to encourage investment in these areas [8][22]. - The regulatory clarity is likely to attract multinational companies to increase their investments in China, potentially leading to global R&D projects being led from China [6][19]. Group 4: Compliance and Quality Management - Companies must establish comprehensive compliance systems to meet the heightened legal obligations imposed by the new regulations [3][16]. - The regulations impose stricter quality management requirements, particularly for online sales and third-party platforms, enhancing accountability [11][26]. - The increased compliance costs may pressure smaller pharmaceutical companies, potentially leading to market consolidation [13][27].